Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

$31.10 -0.27 (-0.86%)

(As of 11/12/2024 ET)

Tandem Diabetes Care - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for Tandem Diabetes Care in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for TNDM.

Consensus Price Target

$54.25
74.44% Upside

According to the 18 analysts' twelve-month price targets for Tandem Diabetes Care, the average price target is $54.25. The highest price target for TNDM is $75.00, while the lowest price target for TNDM is $37.00. The average price target represents a forecasted upside of 74.44% from the current price of $31.10.

TNDM Analyst Ratings Over Time

Type	Current Forecast 11/14/23 to 11/13/24	1 Month Ago 10/15/23 to 10/14/24	3 Months Ago 8/16/23 to 8/15/24	1 Year Ago 11/14/22 to 11/14/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$54.25	$55.13	$55.08	$38.50
Forecasted Upside	74.44% Upside	47.57% Upside	25.69% Upside	116.05% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

TNDM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TNDM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tandem Diabetes Care Stock vs. The Competition

Type	Tandem Diabetes Care	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	78.22% Upside	25,200.76% Upside	7.99% Upside
News Sentiment Rating	Positive News See Recent TNDM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$58.00 ➝ $60.00	+92.86%
11/7/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Buy ➝ Buy	$57.00 ➝ $56.00	+67.16%
11/7/2024	Robert W. Baird 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$39.00 ➝ $37.00	+9.89%
11/6/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Hambright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$42.00	+26.85%
10/4/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$46.00	+13.69%
10/2/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00	+58.27%
2024 Election Year Stocks: Uncover Hidden Gems! (Ad) In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss. Secure your copy now by clicking this link.
9/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$45.00 ➝ $45.00	-2.24%
8/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$50.00 ➝ $55.00	+31.86%
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $55.00	+29.35%
6/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$47.00 ➝ $58.00	+18.73%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+15.94%
5/22/2024	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$60.00 ➝ $75.00	+47.17%
5/22/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $55.00	+11.52%
5/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$40.00 ➝ $57.00	+15.57%
4/25/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$34.00 ➝ $45.00	+28.13%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$47.00 ➝ $45.00	+116.66%
8/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$52.00 ➝ $34.00	+2.87%
6/13/2023	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$74.00 ➝ $50.00	+93.12%
5/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$45.00 ➝ $33.00	-12.02%
4/24/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
2/23/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$61.00 ➝ $52.00	+29.84%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:28 AM ET.

TNDM Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Tandem Diabetes Care is $54.25, with a high forecast of $75.00 and a low forecast of $37.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TNDM shares.
: According to analysts, Tandem Diabetes Care's stock has a predicted upside of 74.44% based on their 12-month stock forecasts.
: Tandem Diabetes Care has been rated by research analysts at Barclays, Canaccord Genuity Group, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, and The Goldman Sachs Group in the past 90 days.
: Analysts like Tandem Diabetes Care less than other "medical" companies. The consensus rating score for Tandem Diabetes Care is 2.78 while the average consensus rating score for "medical" companies is 2.80. Learn more on how TNDM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Trump’s Back, but DC’s Coming for Your Money! (Ad)

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

This page (NASDAQ:TNDM) was last updated on 11/13/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Stock Forecast & Price Target